In a recent open-label pilot study, 20 T2DM patients treated with the DPP-4 inhibitor, Teneligliptin, exhibited improvement of cardiac parasympathetic autonomic function, as measured by the heart rate responding to standing and the heart rate responding to Valsalva maneuver. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.